aTyr Pharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for aTyr Pharma (ATYR).

Price Target Range — 9 Quarters

Analyst Consensus — 8 Analysts

2Buy

6Hold

Consensus RatingBuy# Analysts8Avg. Consensus PT$60Upside to Avg. PT+1060.5%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
May 20, 2026	Freedom Broker	Ilya Zubkov	Upgrade	Hold→Buy	$40→$140
Nov 7, 2025	RBC Capital	Brian Abrahams	PT Cut	Sector Perform	$60→$40
Sep 19, 2025	Freedom Broker	Ilya Zubkov	Downgrade	Buy→Hold	$380→$40
Sep 16, 2025	Wells Fargo	Derek Archila	Downgrade	Overweight→Equal-Weight	$1000→$40
Sep 16, 2025	RBC Capital	Brian Abrahams	Downgrade	Outperform→Sector Perform	$640→$60
Sep 15, 2025	Leerink Partners	Faisal Khurshid	Downgrade	Outperform→Market Perform	$40
Sep 15, 2025	Jones Trading	Soumit Roy	Downgrade	Buy→Hold	—
Sep 15, 2025	Cantor Fitzgerald	Prakhar Agrawal	Downgrade	Overweight→Neutral	—
Sep 15, 2025	LUCID CAPITAL MARKETS	Dev Prasad	Downgrade	Buy→Neutral	$440→$40
Sep 15, 2025	HC Wainwright & Co.	Joseph Pantginis	Downgrade	Buy→Neutral	—
Aug 22, 2025	Jefferies	Roger Song	PT Raise	Buy	$360→$680
Jun 20, 2025	Wells Fargo	Derek Archila	PT Raise	Overweight	$680→$1000
Jun 4, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400
May 19, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400
Mar 14, 2025	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400
Feb 18, 2025	Leerink Partners	Faisal Khurshid	Initiate	Outperform	$640
Jan 6, 2025	Cantor Fitzgerald	Prakhar Agrawal	Initiate	Overweight	—
Dec 10, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400
Dec 3, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400
Oct 29, 2024	HC Wainwright & Co.	Joseph Pantginis	Maintained	Buy	$1400

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1

RBC Capital analyst Brian Abrahams maintains aTyr Pharma (NASDAQ:ATYR) with a Sector Perform and lowers the price target from $1.5 to $1.

Benzinga Newsdesk

Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday

Avi Kapoor

PRO
Wells Fargo Downgrades aTyr Pharma to Equal-Weight, Lowers Price Target to $1

Wells Fargo analyst Derek Archila downgrades aTyr Pharma (NASDAQ:ATYR) from Overweight to Equal-Weight and lowers the price target from $25 to $1.

Benzinga Newsdesk

PRO
RBC Capital Downgrades aTyr Pharma to Sector Perform, Lowers Price Target to $1.5

RBC Capital analyst Brian Abrahams downgrades aTyr Pharma (NASDAQ:ATYR) from Outperform to Sector Perform and lowers the price target from $16 to $1.5.

Benzinga Newsdesk

PRO
HC Wainwright & Co. Downgrades aTyr Pharma to Neutral

HC Wainwright & Co. analyst Joseph Pantginis downgrades aTyr Pharma (NASDAQ:ATYR) from Buy to Neutral.

Benzinga Newsdesk

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday

Avi Kapoor

aTyr Pharma Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

aTyr Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRO
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1

Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday

PRO
Wells Fargo Downgrades aTyr Pharma to Equal-Weight, Lowers Price Target to $1

PRO
RBC Capital Downgrades aTyr Pharma to Sector Perform, Lowers Price Target to $1.5

PRO
HC Wainwright & Co. Downgrades aTyr Pharma to Neutral

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

aTyr Pharma Inc

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

aTyr Pharma Analyst Price Targets

Recent Analyst Actions

Analyst Ratings News

PRORBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1

Goldman Sachs To Rally around 9%? Here Are 10 Top Analyst Forecasts For Tuesday

PROWells Fargo Downgrades aTyr Pharma to Equal-Weight, Lowers Price Target to $1

PRORBC Capital Downgrades aTyr Pharma to Sector Perform, Lowers Price Target to $1.5

PROHC Wainwright & Co. Downgrades aTyr Pharma to Neutral

Nvidia To Rally More Than 22%? Here Are 10 Top Analyst Forecasts For Friday

People Also Watch

People Also Watch

PRO
RBC Capital Maintains Sector Perform on aTyr Pharma, Lowers Price Target to $1

PRO
Wells Fargo Downgrades aTyr Pharma to Equal-Weight, Lowers Price Target to $1

PRO
RBC Capital Downgrades aTyr Pharma to Sector Perform, Lowers Price Target to $1.5

PRO
HC Wainwright & Co. Downgrades aTyr Pharma to Neutral